Advancing the Vision of Comprehensive Cancer Care in Europe

Alex Filicevas is a passionate cancer patient advocate focused on driving meaningful change in... Alex Filicevas is a passionate cancer patient advocate focused on driving meaningful change in cancer research, policy and care. Alex is the Executive Director of the World Bladder Cancer Patient Coalition, President of All.Can International and a EUPATI fellow. He leads the efforts to foster an international community of strong bladder cancer patient advocates and organisations around the world, empowering patient voices across the research and care continuum. Passionate about high-quality, equitable cancer care for all, and the role of efficiency in achieving it, he champions evidence generation and sharing and multi-stakeholder collaboration. Prior to his current roles, he was leading EU affairs work at Europe’s largest cancer patient umbrella organisation, where he focused on advocacy activities, capacity building and policy initiatives with a particular focus on overarching issues faced by cancer patients and their carers in Europe. As a healthcare consultant, Alex has supported a number of private and non-governmental organisations in successful advocacy efforts at the EU level on a range of disease areas and issue-specific public health challenges. Read more Show less

John Gribben is Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts... John Gribben is Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary University of London, UK. After doctoral studies at University College London, where he was the recipient of a Wellcome Trust Fellowship Award, he received a Fogarty International Fellowship to continue postdoctoral training at the Dana- Farber Cancer Institute, Harvard Medical School, in Boston, USA. In 1991, he was appointed to the faculty at Harvard Medical School, where he remained as Associate Professor of Medicine and an attending physician until returning to London in 2005. He is an internationally recognized translational cancer researcher, and the author of more than 490 manuscripts and 60 book chapters. He is a Fellow of the Royal College of Physicians and of the Royal College of Pathologists. He was elected as a member of the American Society for Clinical Investigation and elected as a Fellow of the Academy of Medical Science. Professor Gribben’s primary research interests include advances in the management of lymphoma and CLL, immunotherapy of cancer (including stem-cell transplantation), the identification of tumor antigens, and eradication of minimal residual disease. He was awarded the prestigious Binet-Rai Medal in 2017 for his outstanding contribution to research into CLL. His research work focuses on the impact of B cell malignancies on the host immune system, and delineating the molecular mechanisms for this. He is Board member of the international workshop for CLL. He is the Chair of the international workshop for NHL and co-Chair of the international workshop for CART. He serves on the Executive Board of the European Hematology Association (EHA) and as President of EHA from 2019-2021. Read more Show less

Lorenza Marotti is Eusoma Executive Director and Lead Auditor for “Breast Centres Certification”... Lorenza Marotti is Eusoma Executive Director and Lead Auditor for “Breast Centres Certification” scheme. She has been Founding Member and Member of the Executive Committee of Senonetwork Italia Onlus. Co-author of several papers on breast cancer. Her main interest is quality control in breast cancer care. Read more Show less

Mārcis Leja is Professor of Medicine, Director of the Institute of Clinical and Preventive... Mārcis Leja is Professor of Medicine, Director of the Institute of Clinical and Preventive Medicine, University of Latvia, Head of the Dept. of Research, Riga East University hospital, and a consulting gastroenterologist at the Digestive Diseases Centre. He is a member of the European Cancer Mission Board and the Research Committee of the United European Gastroenterology. His special interest lies in the prevention and early detection of gastrointestinal cancer, particularly - gastric cancer. He is the principal investigator of the population-based gastric cancer prevention study GISTAR (www.gistar.eu). The other area of interest is related to the use of volatile organic marker (VOC) diagnostic concept in gastrointestinal cancer detection as well as for other conditions. Read more Show less

Niko Andre is the Global Head of Immuno-Oncology and Haematology at AstraZeneca, based in... Niko Andre is the Global Head of Immuno-Oncology and Haematology at AstraZeneca, based in Switzerland. Niko is a passionate advocate for improved cancer care. He pursued his medical degree and PhD at the University of Hamburg, Germany and continued his medical career in Germany and the US. As an experienced oncology researcher and treating physician, Niko is adept at translating science into tangible value for patients and effectively collaborating with research and development and with policy. Niko joined AstraZeneca in 2020. He is a proven leader who brings together profound experience in science, clinical medicine and commercial operations in the life science industry. Niko has contributed to building AstraZeneca’s position in oncology leading the Haematology business and now the expansion of the Immuno-Oncology portfolio. Before joining AstraZeneca, he led Roche’s Global Medical Affairs group across all therapeutic areas, following earlier assignments as Global Medical Head Oncology/Hematology and German Medical Director Oncology/Hematology. Niko is an active member of ASCO, AACR, ESMO and the German Cancer Society, maintaining a global network of cancer specialists, advocates and industry leaders. He is eager to collaborate at every possible level towards better outcomes for cancer patients. Read more Show less

A co-chair at Quality Cancer Care Network, European Cancer Organisation. Features in 2 videos on... A co-chair at Quality Cancer Care Network, European Cancer Organisation. Features in 2 videos on Cerebria. Philip Poortmans generally speaks on Oncology, Medical Oncology, Cancer Patients, Health Policy, and Oncology: Webinar. Read more Show less

European Cancer Organisation Quality Cancer Care Network Co-Chair

Professor Albreht is a Senior Health Services and Health Systems Researcher at the National... Professor Albreht is a Senior Health Services and Health Systems Researcher at the National Institute of Public Health of Slovenia. He specializes in social medicine and, having completed his doctorate at the University of Amsterdam, he dedicates his research to the exploration of health services – nationally and internationally. He is particularly interested in the performance of health systems, evidence-based health policy, health workforce planning and mobility, and development of more efficient health care, especially in the field of noncommunicable diseases. Professor Albreht is an associate professor of public health at the Faculty of Medicine, University of Ljubljana, and a member of the Scientific Committee of the European Public Health Association. He acts as a reviewer for several international and national medical and public health journals. Since 2006, he has been actively involved in the development of cancer policies at the European level – during the Slovenian Presidency of the European Council and later as coordinator of Joint Actions on cancer policy at the European Union level, including the European Partnership for Action Against Cancer (EPAAC), Cancer Control (CanCon) and most recently, the Innovative Partnership for Action Against Cancer (iPAAC). Professor Albreht has worked in a number of projects for policy support in various countries of south-eastern Europe (Bosnia and Herzegovina, Macedonia, the Republic of Moldova, Montenegro and Serbia) and also in Kazakhstan. These consultancies have included: support for the development of public health legislation, cancer control and public health interventions. All of these projects were in support of the policies of the respective ministries of health. Read more Show less